Cargando…
Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell dea...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453728/ https://www.ncbi.nlm.nih.gov/pubmed/37626878 http://dx.doi.org/10.3390/cells12162068 |
_version_ | 1785096008237056000 |
---|---|
author | Gonçalves, Lisa Gonçalves, Duarte Esteban-Casanelles, Teresa Barroso, Tiago Soares de Pinho, Inês Lopes-Brás, Raquel Esperança-Martins, Miguel Patel, Vanessa Torres, Sofia Teixeira de Sousa, Rita Mansinho, André Costa, Luís |
author_facet | Gonçalves, Lisa Gonçalves, Duarte Esteban-Casanelles, Teresa Barroso, Tiago Soares de Pinho, Inês Lopes-Brás, Raquel Esperança-Martins, Miguel Patel, Vanessa Torres, Sofia Teixeira de Sousa, Rita Mansinho, André Costa, Luís |
author_sort | Gonçalves, Lisa |
collection | PubMed |
description | Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016–2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04–39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23–0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies. |
format | Online Article Text |
id | pubmed-10453728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104537282023-08-26 Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes Gonçalves, Lisa Gonçalves, Duarte Esteban-Casanelles, Teresa Barroso, Tiago Soares de Pinho, Inês Lopes-Brás, Raquel Esperança-Martins, Miguel Patel, Vanessa Torres, Sofia Teixeira de Sousa, Rita Mansinho, André Costa, Luís Cells Article Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016–2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04–39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23–0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies. MDPI 2023-08-15 /pmc/articles/PMC10453728/ /pubmed/37626878 http://dx.doi.org/10.3390/cells12162068 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gonçalves, Lisa Gonçalves, Duarte Esteban-Casanelles, Teresa Barroso, Tiago Soares de Pinho, Inês Lopes-Brás, Raquel Esperança-Martins, Miguel Patel, Vanessa Torres, Sofia Teixeira de Sousa, Rita Mansinho, André Costa, Luís Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes |
title | Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes |
title_full | Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes |
title_fullStr | Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes |
title_full_unstemmed | Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes |
title_short | Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes |
title_sort | immunotherapy around the clock: impact of infusion timing on stage iv melanoma outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453728/ https://www.ncbi.nlm.nih.gov/pubmed/37626878 http://dx.doi.org/10.3390/cells12162068 |
work_keys_str_mv | AT goncalveslisa immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT goncalvesduarte immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT estebancasanellesteresa immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT barrosotiago immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT soaresdepinhoines immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT lopesbrasraquel immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT esperancamartinsmiguel immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT patelvanessa immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT torressofia immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT teixeiradesousarita immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT mansinhoandre immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes AT costaluis immunotherapyaroundtheclockimpactofinfusiontimingonstageivmelanomaoutcomes |